Patient baseline characteristics
| . | N = 101 . |
|---|---|
| Age, median (range), y | 58 (23-76) |
| ≥65 y, n (%) | 24 (24) |
| Male sex, n (%) | 68 (67) |
| Disease type, n (%) | |
| DLBCL | 77 (76) |
| PMBCL | 8 (8) |
| TFL | 16 (16) |
| Prognostic marker per central laboratory, n (%) | |
| HGBL – double hit | 3 (3) |
| HGBL – triple hit | 1 (1) |
| HGBL-NOS | 2 (2) |
| Double-expressor lymphoma | 27 (27) |
| No HGBL/tested negative | 7 (7) |
| N/A | 2 (2) |
| Not tested | 59 (58) |
| Previous therapies, n (%) | |
| ASCT | 25 (25) |
| Platinum based | 90 (89) |
| Response to most recent prior therapy, n (%)∗ | |
| SD | 13 (13) |
| PD | 67 (66) |
| Lymphoma present in bone marrow, n (%) | 8 (8) |
| LDH > ULN, n (%) | 85 (84) |
| Sum of product diameters, median (range), mm2 | 3723 (171-23 297) |
| . | N = 101 . |
|---|---|
| Age, median (range), y | 58 (23-76) |
| ≥65 y, n (%) | 24 (24) |
| Male sex, n (%) | 68 (67) |
| Disease type, n (%) | |
| DLBCL | 77 (76) |
| PMBCL | 8 (8) |
| TFL | 16 (16) |
| Prognostic marker per central laboratory, n (%) | |
| HGBL – double hit | 3 (3) |
| HGBL – triple hit | 1 (1) |
| HGBL-NOS | 2 (2) |
| Double-expressor lymphoma | 27 (27) |
| No HGBL/tested negative | 7 (7) |
| N/A | 2 (2) |
| Not tested | 59 (58) |
| Previous therapies, n (%) | |
| ASCT | 25 (25) |
| Platinum based | 90 (89) |
| Response to most recent prior therapy, n (%)∗ | |
| SD | 13 (13) |
| PD | 67 (66) |
| Lymphoma present in bone marrow, n (%) | 8 (8) |
| LDH > ULN, n (%) | 85 (84) |
| Sum of product diameters, median (range), mm2 | 3723 (171-23 297) |
ASCT, autologous SCT; HGBL, high-grade B-cell lymphoma; LDH, lactate dehydrogenase; N/A, not available; NOS, not otherwise specified; PD, progressive disease; PMBCL, primary mediastinal B-cell lymphoma; SD, stable disease; TFL, transformed follicular lymphoma; ULN, upper limit of normal.
Patients included those who did not relapse after ASCT.